Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Contributed by: Business Wire

Logo

Tags

Oncology

Health

FDA

Other Health

Clinical Trials

Pharmaceutical

Biotechnology

Alentis Therapeutics

More Like This

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Dr. William Pao has joined Alentis Therapeutics' Board of Directors as an independent member. (Photo: Alentis Therapeutics)

William Pao Joins Alentis Therapeutics as Independent Board Member

Alberto Toso, Chief Scientific Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Alentis Appoints Alberto Toso Chief Scientific Officer

Jon Freve, Chief Financial Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Alentis Appoints Jonathan Freve CFO

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib